<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129427</url>
  </required_header>
  <id_info>
    <org_study_id>INT11374</org_study_id>
    <nct_id>NCT01129427</nct_id>
  </id_info>
  <brief_title>Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects</brief_title>
  <official_title>A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomitantly With Pantoprazole 80 mg/Day in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
        -  Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on&#xD;
           Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with&#xD;
           pantoprazole 80 mg/day compared to given alone in healthy male subjects&#xD;
&#xD;
        -  Compare the pharmacokinetic profiles of clopidogrel active metabolite when clopidogrel&#xD;
           is given either alone or concomitantly with pantoprazole&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  Compare the pharmacokinetic profiles of clopidogrel when clopidogrel is given either&#xD;
           alone or concomitantly with pantoprazole&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per subjects is 8 - 9 weeks broken down as follows:&#xD;
&#xD;
        -  Screening: 2 to 21 days before the first dosing&#xD;
&#xD;
        -  Period clopidogrel/placebo: 7 days including 5 days treatment&#xD;
&#xD;
        -  Period clopidogrel/placebo + pantoprazole: 14 days including 12 days treatment&#xD;
&#xD;
        -  Washout between periods: at least 14 days after last dosing with respect to clopidogrel&#xD;
           treatment&#xD;
&#xD;
        -  End of study: 7 to 10 days after the last dosing&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum platelet aggregation intensity (MAI) induced by Adenosine diphosphate (ADP) 5µM after 5 days treatment</measure>
    <time_frame>Day 5 of each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clopidogrel active metabolite pharmacokinetic parameters (maximum plasma concentration (Cmax) and area under the plasma concentration curve (AUC0-24)) after 5 days treatment</measure>
    <time_frame>Up to 24 hours postdose on Day 5 of each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum platelet aggregation intensity (MAI) induced by ADP 20µM after 5 days treatment</measure>
    <time_frame>Day 5 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Index - Vasodilatator-stimulated phosphoprotein test (PRI - VASP) after 5 days treatment</measure>
    <time_frame>Day 5 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clopidogrel pharmacokinetic parameters (Cmax and AUC0-24) after 5 days treatment</measure>
    <time_frame>Up to 24 hours postdose on Day 5 for each period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group clopidogrel - clopidogrel + pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:&#xD;
Day 1: clopidogrel 300 mg loading dose&#xD;
Day 2 to Day 5: clopidogrel 75 mg, once daily&#xD;
Period 2:&#xD;
Day -7 to Day -1: pantoprazole 80 mg, once daily&#xD;
Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly&#xD;
Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily&#xD;
Each intake is under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group placebo - placebo + pantoprazole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period 1:&#xD;
Day 1: placebo loading dose&#xD;
Day 2 to Day 5: placebo, once daily&#xD;
Period 2:&#xD;
Day -7 to Day -1: pantoprazole 80 mg, once daily&#xD;
Day 1: placebo loading dose + pantoprazole 80 mg concomitantly&#xD;
Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily&#xD;
Each intake is under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group clopidogrel + pantoprazole - clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:&#xD;
Day -7 to Day -1: pantoprazole 80 mg, once daily&#xD;
Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly&#xD;
Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily&#xD;
Period 2:&#xD;
Day 1: clopidogrel 300 mg loading dose&#xD;
Day 2 to Day 5: clopidogrel 75 mg, once daily&#xD;
Each intake is under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group placebo + pantoprazole placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period 1:&#xD;
Day -7 to Day -1: pantoprazole 80 mg, once daily&#xD;
Day 1: placebo loading dose + pantoprazole 80 mg concomitantly&#xD;
Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily&#xD;
Period 2:&#xD;
Day 1: placebo loading dose&#xD;
Day 2 to Day 5: placebo, once daily&#xD;
Each intake is under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Group clopidogrel + pantoprazole - clopidogrel</arm_group_label>
    <arm_group_label>Group clopidogrel - clopidogrel + pantoprazole</arm_group_label>
    <other_name>SR25990</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: matching tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Group placebo + pantoprazole placebo</arm_group_label>
    <arm_group_label>Group placebo - placebo + pantoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>Pharmaceutical form: delayed-release tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Group clopidogrel + pantoprazole - clopidogrel</arm_group_label>
    <arm_group_label>Group clopidogrel - clopidogrel + pantoprazole</arm_group_label>
    <arm_group_label>Group placebo + pantoprazole placebo</arm_group_label>
    <arm_group_label>Group placebo - placebo + pantoprazole</arm_group_label>
    <other_name>PROTONIX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy male subject:&#xD;
&#xD;
          -  as determined by medical history, physical examination including vital signs and&#xD;
             clinical laboratory tests:&#xD;
&#xD;
          -  with a body weight between 50 kg and 95 kg and with a Body Mass Index (BMI) between 18&#xD;
             and 30 kg/m²&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of inherited disorder of coagulation/hemostasis functions&#xD;
&#xD;
          -  Smoking more than 5 cigarettes or equivalent per day&#xD;
&#xD;
          -  Abnormal hemostasis screen&#xD;
&#xD;
          -  Unability to abstain from intake of any drug affecting hemostasis throughout the whole&#xD;
             study duration&#xD;
&#xD;
          -  Any contraindication to clopidogrel and/or pantoprazole&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>International Clinical Development Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011 Jan;89(1):65-74. doi: 10.1038/clpt.2010.219. Epub 2010 Sep 15.</citation>
    <PMID>20844485</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>December 14, 2011</last_update_submitted>
  <last_update_submitted_qc>December 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

